Matthew Hamar, DO
Family Medicine · Bismarck, NDNPI 1154618130
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. 2022 is the largest year on record at $970, 2.8 times the $344 reported in 2019.
Across 137 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$270
- AstraZeneca$225
- AbbVie$207
- Astellas Pharma US Inc$206
- Novartis$173
- Pfizer$144
- plus $855 from 10 others
What the payments were for
- Food & beverage$2,073100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 20 | $270 |
| AstraZeneca | 16 | $225 |
| AbbVie(2 entities) | 12 | $207 |
| Astellas Pharma US Inc | 13 | $206 |
| Novartis | 9 | $173 |
| Pfizer | 9 | $144 |
| Novo Nordisk | 9 | $143 |
| Lilly USA, LLC | 11 | $140 |
| Sanofi-aventis U.S. LLC | 8 | $135 |
| Johnson & Johnson | 6 | $90 |
| Abbott | 6 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $80 |
| Bayer | 5 | $70 |
| Boehringer Ingelheim | 4 | $60 |
| Merck | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$2,079 in reported general payments places this provider in the 85th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 401 | $239,790 |
| TrulicityDulaglutide | 152 | $159,683 |
| OzempicSemaglutide | 116 | $121,767 |
| JardianceEmpagliflozin | 143 | $121,375 |
| MounjaroTirzepatide | 73 | $92,924 |
| FarxigaDapagliflozin Propanediol | 103 | $84,709 |
| XareltoRivaroxaban | 116 | $77,944 |
| RybelsusSemaglutide | 28 | $46,480 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $39,146 |
| JanuviaSitagliptin Phosphate | 50 | $37,221 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $19,562 |
| MyrbetriqMirabegron | 34 | $19,527 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 105 | $16,353 |
| GlyxambiEmpagliflozin/Linagliptin | 26 | $15,017 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $14,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $140 | $252,606225 claims |
| PfizerEliquis | $144 | $239,790401 claims |
| Novo NordiskOzempic, Rybelsus | $143 | $168,247144 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $60 | $145,919188 claims |
| AstraZenecaFarxiga, Symbicort | $225 | $89,580116 claims |
| Johnson & JohnsonXarelto, Invokana | $90 | $84,953128 claims |
| MerckJanuvia, Janumet | $38 | $46,57264 claims |
| Astellas Pharma US IncMyrbetriq | $206 | $19,52734 claims |
| AbbVieLinzess, Synthroid | $207 | $18,54091 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $135 | $14,82315 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $11,64915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Bismarck
- Jacqueline QuisnoBismarck$19K
- Jeffrey SmithBismarck$15K
- Stuart SmithBismarck$8K
- David PengillyBismarck$8K
- Biron BakerBismarck$8K
- Michelle TincherBismarck$7K
- Kevin LongieBismarck$6K
- Kelly LongieBismarck$5K
- Sherry SteinBismarck$5K
- David FieldBismarck$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.